Renewed US pressure on pharmaceutical pricing, including the emergence of Most Favored Nation concepts under the Donald Trump administration, should not be dismissed as irrelevant to Australian policy debates or characterised as an illegitimate intrusion into domestic decision-making.
This might be the real once-in-a-generation opportunity achieve reform
February 11, 2026 Latest NewsBioPharma
Latest Video
New Stories
-
Moderna expands support for early career Australian mRNA researchers
May 7, 2026 - - Latest News -
The review is formally over. Why is it restarting?
May 7, 2026 - - Latest News -
AI screening tool gives pathologists 'super' vision to detect hidden cancer
May 7, 2026 - - Latest News -
Australian company celebrated in centenary project on royal and parliamentary leadership
May 6, 2026 - - Latest News -
La Trobe launches REACH program to fight antimicrobial resistance
May 6, 2026 - - Latest News -
If the imperative is international comparison, why limit it to these definitions?
May 5, 2026 - - Latest News -
Therapy funded three years after the 'clunky' and 'preventable deaths' admission
May 5, 2026 - - Latest News
